移植前合并症对移植后5年同种异体干细胞移植结果的影响:一项来自德国一家机构的回顾性研究。

ISRN Hematology Pub Date : 2014-03-05 eCollection Date: 2014-01-01 DOI:10.1155/2014/853435
Jens M Chemnitz, Geothy Chakupurakal, Maya Bäßler, Udo Holtick, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Silke Leitzke, Michael S Von Bergwelt-Baildon, Christof Scheid
{"title":"移植前合并症对移植后5年同种异体干细胞移植结果的影响:一项来自德国一家机构的回顾性研究。","authors":"Jens M Chemnitz,&nbsp;Geothy Chakupurakal,&nbsp;Maya Bäßler,&nbsp;Udo Holtick,&nbsp;Sebastian Theurich,&nbsp;Alexander Shimabukuro-Vornhagen,&nbsp;Silke Leitzke,&nbsp;Michael S Von Bergwelt-Baildon,&nbsp;Christof Scheid","doi":"10.1155/2014/853435","DOIUrl":null,"url":null,"abstract":"<p><p>The introduction of reduced-intensity conditioning regimens has allowed elderly patients with preexisting comorbidities access to the potentially curative allogeneic stem cell transplantation. Patient's comorbidities at the time of treatment consideration play a significant role in transplant outcome in terms of both overall survival (OS) and nonrelapse mortality (NRM). The hematopoietic stem cell transplantation comorbidity index (HCT-CI) quantifies these patient specific risks and has established itself as a major tool in the pretransplant assessment of patients. Many single center and multicenter studies have assessed the HCT-CI score and reported conflicting outcomes. The present study aimed to evaluate the HCT-CI in a single large European transplant centre. 245 patients were retrospectively analyzed and the predictive value of the score was assessed with respect to OS and NRM. We confirm that the HCT-CI predicts outcome for both OS and NRM. Moreover, we identified age of the patient as an independent prognostic parameter for OS. Incorporation of age in the HCT-CI would improve its ability to prognosticate and allow the transplant physician to assess the patient specific risks appropriately at the time of counseling for transplant. </p>","PeriodicalId":14727,"journal":{"name":"ISRN Hematology","volume":"2014 ","pages":"853435"},"PeriodicalIF":0.0000,"publicationDate":"2014-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/853435","citationCount":"7","resultStr":"{\"title\":\"Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.\",\"authors\":\"Jens M Chemnitz,&nbsp;Geothy Chakupurakal,&nbsp;Maya Bäßler,&nbsp;Udo Holtick,&nbsp;Sebastian Theurich,&nbsp;Alexander Shimabukuro-Vornhagen,&nbsp;Silke Leitzke,&nbsp;Michael S Von Bergwelt-Baildon,&nbsp;Christof Scheid\",\"doi\":\"10.1155/2014/853435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The introduction of reduced-intensity conditioning regimens has allowed elderly patients with preexisting comorbidities access to the potentially curative allogeneic stem cell transplantation. Patient's comorbidities at the time of treatment consideration play a significant role in transplant outcome in terms of both overall survival (OS) and nonrelapse mortality (NRM). The hematopoietic stem cell transplantation comorbidity index (HCT-CI) quantifies these patient specific risks and has established itself as a major tool in the pretransplant assessment of patients. Many single center and multicenter studies have assessed the HCT-CI score and reported conflicting outcomes. The present study aimed to evaluate the HCT-CI in a single large European transplant centre. 245 patients were retrospectively analyzed and the predictive value of the score was assessed with respect to OS and NRM. We confirm that the HCT-CI predicts outcome for both OS and NRM. Moreover, we identified age of the patient as an independent prognostic parameter for OS. Incorporation of age in the HCT-CI would improve its ability to prognosticate and allow the transplant physician to assess the patient specific risks appropriately at the time of counseling for transplant. </p>\",\"PeriodicalId\":14727,\"journal\":{\"name\":\"ISRN Hematology\",\"volume\":\"2014 \",\"pages\":\"853435\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2014/853435\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ISRN Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2014/853435\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2014/853435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

摘要

低强度调节方案的引入,使已有合并症的老年患者有机会接受可能治愈的同种异体干细胞移植。考虑治疗时患者的合并症对移植结果的总生存期(OS)和非复发死亡率(NRM)都起着重要的作用。造血干细胞移植共病指数(HCT-CI)量化了这些患者特定的风险,并已成为患者移植前评估的主要工具。许多单中心和多中心研究评估了HCT-CI评分,并报告了相互矛盾的结果。本研究旨在评估单个大型欧洲移植中心的HCT-CI。对245例患者进行回顾性分析,并评估评分对OS和NRM的预测价值。我们证实HCT-CI可以预测OS和NRM的预后。此外,我们将患者的年龄确定为OS的独立预后参数。将年龄纳入HCT-CI将提高其预测能力,并允许移植医生在进行移植咨询时适当评估患者的特定风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.

The introduction of reduced-intensity conditioning regimens has allowed elderly patients with preexisting comorbidities access to the potentially curative allogeneic stem cell transplantation. Patient's comorbidities at the time of treatment consideration play a significant role in transplant outcome in terms of both overall survival (OS) and nonrelapse mortality (NRM). The hematopoietic stem cell transplantation comorbidity index (HCT-CI) quantifies these patient specific risks and has established itself as a major tool in the pretransplant assessment of patients. Many single center and multicenter studies have assessed the HCT-CI score and reported conflicting outcomes. The present study aimed to evaluate the HCT-CI in a single large European transplant centre. 245 patients were retrospectively analyzed and the predictive value of the score was assessed with respect to OS and NRM. We confirm that the HCT-CI predicts outcome for both OS and NRM. Moreover, we identified age of the patient as an independent prognostic parameter for OS. Incorporation of age in the HCT-CI would improve its ability to prognosticate and allow the transplant physician to assess the patient specific risks appropriately at the time of counseling for transplant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preventative effects of caffeic Acid phenyl ester on cadmium intoxication induced hematological and blood coagulation disturbances and hepatorenal damage in rats. Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. Phagocytized neutrophil fragments in the bone marrow: a phenomenon most commonly associated with hodgkin lymphoma. Coexisting iron deficiency anemia and Beta thalassemia trait: effect of iron therapy on red cell parameters and hemoglobin subtypes. Prevalence of deletional alpha thalassemia and sickle gene in a tribal dominated malaria endemic area of eastern India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1